Photys
Arthur J. Campbell is a seasoned professional in the field of computational chemistry, currently serving as the Senior Director of Computational Chemistry (CADD) at Photys Therapeutics since March 2022, focusing on targeted post-translational modifications for disease treatment. Prior experience includes leadership roles at the Broad Institute of MIT and Harvard from July 2014 to February 2022 and various positions at AstraZeneca between 2011 and 2014, including Senior Scientist in Infection Computational Sciences. Arthur J. Campbell's academic background includes a Doctorate from Stony Brook University, where coursework was completed from August 2005 to March 2011, and a Bachelor's degree in Chemistry from Stony Brook University acquired between 2001 and 2004.
This person is not in any teams
This person is not in any offices
Photys
3 followers
Photys Therapeutics’ proprietary bifunctional small molecules platform unlocks fine-tuned control of protein post-translational modifications, going beyond degradation to restore protein function, repair signaling, and amplify endogenous disease-fighting mechanisms. Photys was co-founded by the Broad Institute’s leading bifunctional chemist, Amit Choudhary, and the Longwood Fund, alongside a scientific advisory board comprised of distinguished scientists and drug developers – MIT’s Angela Koehler, Salk’s Tony Hunter, Berkeley’s Dan Nomura, MPM’s Wendy Young, and Dana Farber’s Eric Fischer.
Employees
11-50